KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Prepaid Assets (2017 - 2025)

Teva Pharmaceutical Industries' Prepaid Assets history spans 10 years, with the latest figure at $1.1 billion for Q4 2025.

  • For the quarter ending Q4 2025, Prepaid Assets rose 11.53% year-over-year to $1.1 billion, compared with a TTM value of $1.1 billion through Dec 2025, up 11.53%, and an annual FY2025 reading of $1.1 billion, up 11.53% over the prior year.
  • Prepaid Assets for Q4 2025 was $1.1 billion at Teva Pharmaceutical Industries, up from $477.0 million in the prior quarter.
  • The five-year high for Prepaid Assets was $1.2 billion in Q2 2023, with the low at $477.0 million in Q3 2025.
  • Average Prepaid Assets over 5 years is $849.2 million, with a median of $1.0 billion recorded in 2024.
  • Year-over-year, Prepaid Assets skyrocketed 137.07% in 2023 and then tumbled 57.9% in 2024.
  • Tracing TEVA's Prepaid Assets over 5 years: stood at $1.1 billion in 2021, then increased by 8.09% to $1.2 billion in 2022, then tumbled by 56.63% to $504.0 million in 2023, then soared by 99.6% to $1.0 billion in 2024, then grew by 11.53% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Prepaid Assets are $1.1 billion (Q4 2025), $477.0 million (Q3 2025), and $1.1 billion (Q2 2025).